Table 2.
In-hospital stay and treatment received according to discontinuation or continuation of RASIs
| RASIs discontinued n=340 (%) |
RASIs continued n=285 (%) |
Standardised difference | p value | |
|---|---|---|---|---|
| Hospital stay, days, median (IQR) | 11 (7.5–17) | 10 (7–16) | +0.01 | 0.17 |
| ICU admission | 19 (5.6) | 17 (6.0) | +0.02 | 0.84 |
| Anticoagulants | ||||
| Oral | 26 (7.7) | 42 (14.7) | −0.23 | 0.01 |
| Parenteral | 273 (80.3) | 166 (58.2) | +0.49 | <0.001 |
| Antiplatelet drugs | 80 (23.5) | 86 (30.2) | −0.15 | 0.06 |
| Statins | 46 (13.5) | 113 (39.7) | −0.62 | <0.001 |
| Glucose lowering drugs | ||||
| Oral | 14 (4.1) | 43 (15.1) | −0.38 | <0.001 |
| Insulin | 125 (36.8) | 90 (31.6) | +0.11 | 0.17 |
| Hydroxychloroquine | 306 (90.0) | 244 (85.6) | +0.13 | 0.09 |
| Lopinavir+Ritonavir/Darunavir+Cobicistat | 286 (84.1) | 233 (81.8) | +0.06 | 0.43 |
| Azithromycin | 128 (37.7) | 116 (40.7) | −0.06 | 0.44 |
| Other macrolides | 10 (2.9) | 19 (6.7) | −0.17 | 0.03 |
| Other antivirals* | 8 (2.4) | 6 (2.1) | +0.02 | 0.84 |
| Other antibacterial agents | 212 (62.4) | 194 (68.1) | −0.12 | 0.14 |
| Immunomodulators | ||||
| Tocilizumab | 43 (12.7) | 57 (20.0) | −0.20 | 0.01 |
| Others** | 99 (29.1) | 121 (42.5) | −0.28 | <0.001 |
| Corticosteroids | 167 (49.1) | 112 (39.3) | +0.20 | 0.01 |
| Antihypertensive drugs | ||||
| CCBs | 131 (38.5) | 70 (24.6) | +0.30 | <0.001 |
| Beta-blockers | 60 (17.7) | 69 (24.2) | −0.16 | 0.04 |
| Alpha-blockers | 11 (3.2) | 9 (3.2) | +0.004 | 0.96 |
| High-ceiling diuretics | 52 (15.3) | 44 (15.4) | −0.004 | 0.96 |
| Low-ceiling diuretics | 17 (5.0) | 53 (18.6) | −0.43 | <0.001 |
Abbreviations: CCBs calcium channel blockers, ICU intensive care unit, IQR interquartile range, RASIs renin-angiotensin system inhibitors
*Other antivirals: remdesivir, aciclovir, bictegravir-emtricitabine-tenofovir, tenofovir, emtricitabine-tenofovir, lamivudine-abacabir-dolutegravir, valaciclovir, and valganciclovir
**Other immunomodulators: Jak inhibitors, interferon beta-1b, ciclosporin, anakinra, ceftriaxone, leflunomide, methotrexate, and mycophenolic acid